Welcome readers,
Our lead article explores how life sciences real estate has become a feature of diverse European investment funds — varying in geography, sector focus, and investment style. This edition also covers 23 deals across Europe, spanning new developments, expansions, leases, and fund activity. Highlights include major projects from Roche in Basel, Eli Lilly in Leiden, AstraZeneca in Barcelona, and Centillion’s new lease at Cambridge Research Park.
🔒 Paying subscribers get 23 deals • Everyone else can explore 3 of them → Get full access by subscribing here.
— Stephen Ryan (connect with me on LinkedIn)
🔍 Do you need deeper insights into life sciences real estate?
In addition to our regular updates, we offer bespoke research and strategic analysis for investors and developers in the life sciences sector. Whether you’re evaluating an acquisition, tracking market trends, or need a custom report, our team can help you make informed decisions.
Get in touch to discuss how we can support your next project.
Featured article of the week
The four types of real estate fund investing in Europe’s life sciences sector
From pan-European specialists to national core funds, four distinct fund types are driving investment in life sciences real estate.
Deals
BELGIUM GHENT
The Flemish Institute for Biotechnology is building a new headquarters and bio-incubator at the Tech Lane Science Park, Ghent. This €55 million building extends to 9,500 sq m over eight storeys and will become operational in late 2026, offering flexible lab units for biotech and pharma scale-ups. Finance was provided by PMV, the Flemish government investment company, along with additional support from the European Regional Development Fund (ERDF).
BELGIUM LEUVEN
The Infinity Lab opened in October 2025 at Flanders Make, a joint project of KU Leuven and VIVES University of Applied Sciences. The facility provides advanced laboratory space dedicated to industry-university collaboration in robotics, automation and smart manufacturing for health and life sciences. The investment in equipment and infrastructure totalled approximately € 1.7 million.
Would you like instant access to more deals like these? Our data tool lets you filter, sort and search European life sciences transactions spanning 24 countries—whether you're tracking a single city or spotting market patterns others miss.
GERMANY DARMSTADT
Merck opened its Launch and Technology Center in Q3 2025 at its Darmstadt headquarters. The €160 million building spans 14,000 sq m and supports technology transfer between research and manufacturing, accelerating the market launch of small molecule-based medicines. The facility includes laboratories, offices and flexible production areas, enabling Merck to internalise activities previously outsourced. The centre is expected to be fully operational by 2026.
👇 As a free member, you get access to three deals for free.
Upgrade now to access the full list.
